Re: Teva slips on reports of study linking MS drugs to cancer

Maybe I am naive but, what is LDN. I have never heard of it.
I have NEVER taken any meds for MS. I was diagnosed at end stage
Secondary Progressive and am moving into Primary Progressive. Do you,
Big Artie, know of anything that will halt my progression or better
still put me back to where I was a few years ago?
I really hope you have an answer for me. The doctors have given up. I
am into the "there is nothing more I can do" syndrome and I refuse to
believe that yet. Maybe in a while but not yet.

M

On Sun, 12 Aug 2007 13:56:42 -0400, "BigArtie" <badegg69@xxxxxxxxxxx>
wrote:


"BigArtie" <badegg69@xxxxxxxxxxx> wrote in message
news:5zCui.3$Jn6.1@xxxxxxxxxxxxxxx
Teva slips on reports of study linking MS drugs to cancer

By Nitzan Cohen and Yoram Gavison

Drugmaker Teva Pharmaceuticals lost 3 percent on huge turnover of NIS 89
million yesterday on the Tel Aviv Stock Exchange on rumors of research
linking the company's multiple sclerosis treatment Copaxone with breast
cancer.

The research, headed by Ben-Gurion University's Dr Anat Ahiron, was
submitted for publication in medical journal Breast Cancer Research &
Treatment, and is based on the results of earlier studies.

Those studies found that MS patients not treated with one of the four
medications currently on the market had a smaller chance of contracting
certain forms of cancer than those treated with Biogen's Avonex, Teva's
Copaxone, Serono's Rebif or Schering's Betaserone.

The possible explanation is that MS - an autoimmune disorder in which the
immune system attacks the body - causes intensive immune system activity
that decreases the occurence of cancer. The news in Ahiron's research is
that treatment with MS medications annulled the protective effect the
disease has against cancer.

Ahiron and her research partners examined the effect of treatment with the
four medications on the frequency of cancer in 1,338 patients, 892 of whom
were women. The number is representative of the greater number of females
affected by MS, considered a scourge of women from the northern
hemisphere.

The research found that 15 women contracted breast cancer, and 31 fell ill
with some form of cancer. The research revealed that treatment with
Copaxone increased the chances of contracting breast cancer to greater
than that of the general population. The other three treatments reduced
the chances by 48 percent.

The research revealed that the other three treatments increased the
chances of contracting other forms of cancer. The findings are substantial
enough to indicate the need for further research.

Teva stated in response that Ahiron's data indicated 15 women developed
breast cancer out of the total 892 female patients in the study, but 11
had contracted the disease before beginning treatment for MS. Teva notes
that since the inception of the Copaxone treatment in 1996, 60,000 women
worldwide have taken the drug and been under medical supervision from the
start of treatment. Incidence of cancer in that group is 83 percent lower
than in the general population. This wide database is more reliable than
Ahiron's research population, Teva states.

Investment bank IBI analyst Ela Alkalai said the research could adversely
impact Teva in the short run, due to the U.S. market's sensitivity to drug
safety.

However, Alkalai does not expect the U.S. Food and Drug Administration to
take any action.

Alkalai did note that the research will increase the scrutiny Teva faces
in light of the launch of Copaxone rival Tysabri. She left her buy
recommendation in tact with a $35 target price. She says the current
market price of $28.5 already incorporates a projected dip in Copaxone
sales in 2005.

http://www.haaretzdaily.com/hasen/objects/pages/PrintArticleEn.jhtml?itemNo=528464


Since I started taking LDN and seeing others benefit at halting disease
progression on LDN I truly think that the immune system is under-active
instead of over-active(scientists think) in some cancers and auto-immune
diseases.

The article says that the CRAB drugs are suppressing the immune system so
low that one has no defense left to their immune system and cancer can creep
in. I 100% believe this to be true. I haven't seen a CRAB drug TREAT MS yet.
Treating MS would mean that symptoms and the disease gets better and easier
to live with. Some people on the CRAB's have seen their MS slow down in
progression but there aren't many that are claiming a slowing down in
progression. And what irritates me is that a doctor knowing their patient is
still progressing rapidly on one of the CRAB's continues to keep that person
on the med even though it's failing miserably. And after ALL the FDA
approved MS drugs have failed a person, they STILL REFUSE to write a script
for LDN. MS is THOUGHT(theory) to be over-active. It's still a theory,
they(NMSS) haven't proven that theory. Dr. Bihari believes that in MS the
immune system is under-active(theory), but look at how many people are
benefitting on LDN over the CRAB's.

I believe in the next 10 to 15 years we are going to see cancer way out of
hand in people who have taken and are taking these immune system lowering MS
drugs. I think these CRAB drugs are leaving the immune system very
vulnerable. Like staying on chemo for life.

This is just my opinion, not a professional opinion.


.

Relevant Pages

  • Cancer patient begs for drug
    ... A CANCER patient, suffering from Stage Four lung cancer, has been joined by ... drug available that she has credited for saving her life. ... received from her family and friends and a pill called Naltrexone, ... Jacinta has also undergone chemotherapy and treatment at the Beacon Clinic ...
    (alt.support.mult-sclerosis)
  • Re: Cancer therapy based on anatomical location may soon be obsolete
    ... they saw that whether the tumor was, for instance, a breast tumor, lung ... standard anticancer drug. ... Their findings suggest that traditional cancer treatments -- which have ... Treatment choice would be determined by how each patient's tumor ...
    (sci.med.diseases.cancer)
  • Re: Teva slips on reports of study linking MS drugs to cancer
    ... Drugmaker Teva Pharmaceuticals lost 3 percent on huge turnover of NIS 89 ... submitted for publication in medical journal Breast Cancer Research & ... Treatment, and is based on the results of earlier studies. ... impact Teva in the short run, due to the U.S. market's sensitivity to drug ...
    (alt.support.mult-sclerosis)
  • Re: Way Off Topic: West coast eyes
    ... >>While I harbor a healthy suspicion of drug company claims in general, ... >>Cancer Institute, who led the Gleevec study, sees this treatment as a ... The treatment is based ... > attempt to effect the mutant cells responsible for the cancer. ...
    (rec.woodworking)
  • Re: Greedy Doctors
    ... finding "noteworthy cases of survival" among cancer patients using the ... Hoxsey herbal treatment. ... The face of cancer treatment may soon become almost ... alternative-medicine movement in American history. ...
    (soc.culture.singapore)
Loading